Naslov
Suprahepatic inferior caval vein occlusion and reperfusion in rats induced portal and caval hypertension, aortic hypotension, and esophageal bleeding. therapy with pentadecapeptide BPC 157
(Suprahepatic inferior caval vein occlusion and reperfusion in rats induced portal and caval hypertension, aortic hypotension, and esophageal bleeding. therapy with pentadecapeptide BPC 157)

Autori
Gojković, Slaven ; Krezić, Ivan ; Žižek, Helena ; Malekinušić, Dominik ; Đurašin, Tajana ; Drmić, Domagoj ; Horvat, Katarina ; Seiwerth, Sven ; Sikirić, Predrag

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Gastroenterology (New York, N.Y. 1943), 156 (2019), 6(S) / - , 2019, S-561

Skup
Digestive Disease Week

Mjesto i datum
San Diego (CA), Sjedinjene Američke Države, 18.05.2019. - 21.05.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
inferior caval vein occlusion ; BPC 157

Sažetak
Aim. Pentadecapeptide BPC 157 therapy in a suprahepatic inferior caval vein (ICV) occlusion 15 min, 24h, 48h, and in 15 min reperfusion period after 15 min ICV occlusion. Suprahepatic ICV complications that were counteracted by BPC 157 included esophageal bleeding, severe portal and caval hypertension, and aortal hypotension (assessed as described Vascul Pharmacol 2018 ; 106:54-66). Previously, in rats with portal triad obstruction, BPC 157 counteracts portal hypertension and caval hypotension (Gastroenterology 2015, Vol. 148, Issue 4, S650) ; portal and caval hypertension in rats with short- lasting suprahepatic occlusion of ICV (Gastroenterology, Vol. 154, Issue 6, Supplement 1, s-532) ; portal hypertension in bile duct ligated rats (Gastroenterology 154, Issue 6, Suppl 1, s-536) ; caval hypertension and aortal hypotension after infrarenal ICV occlusion (Vascul Pharmacol 2018 ; 106:54-66). Likewise, BPC 157 counteracts the lesions in the whole GI- tract (Curr Pharm Des 2018 ; 24(18):1990- 2001). Methods: Medication (BPC 157 (10 μg/kg, 10 ng/kg), or saline (5 ml/kg) (controls)) was applied as an abdominal bath immediately after ICV occlusion, or at 1 min reperfusion time. Results: ICV occlusion produced severe esophageal bleeding in all controls, along with microscopy findings. Contrarily, given either in ischemic period or in reperfusion period, BPC 157 counteracts severe esophageal bleeding and maintained grossly intact esophageal mucosa (Fisher exact probability test P≤0.05 at least vs. control)). In rats with ICV occlusion, assessment(means±SD mmHg) of portal, caval and aortal pressure showed huge portal hypertension and more caval hypertension, along with mild aortic hypotension (at the end of the 15 min 68±4 (portal vein), 45±4 (ICV), 73±3 (abdominal aorta), 24 h 56±5 (portal vein), 49±5 (ICV), 35±3 (abdominal aorta) or 48 h 30±3 (portal vein), 48±5 (ICV), 39±3 (abdominal aorta)-ligation period). Contrarily, BPC 157 in rats with suprahepatic ICV occlusion markedly counteracted portal and caval hypertension, and arterial hypotension (10 μg/kg bath (at 15 min: 3±1 (portal vein), 9±1 (ICV), 117±5 (abdominal aorta) ; 24 h: 5±1 (portal vein), 9±1 (ICV), 67±5 (abdominal aorta) or 48 h: 5±1 (portal vein), 9±1 (ICV), 70±6 (abdominal aorta)) ; 10 ng/kg bath produced similar results. At 15 min reperfusion period after 15 min ICV occlusion, we noted 37±5 (portal vein), 68±5 (ICV), 52±3 (abdominal aorta) in controls, and in BPC 157 10 μg/kg 15±2 (portal vein), 8±2 (ICV), 18±3 (abdominal aorta) (*P≤0.05, at least vs. control). Conclusion. BPC 157 therapy successfully counteracts the adverse effects of the suprahepatic ICV occlusion and reperfusion.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA